# A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

> **NCT00737555** · PHASE1 · COMPLETED · sponsor: **Chroma Therapeutics** · enrollment: 23 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** CHR-2797

## Key facts

- **NCT ID:** NCT00737555
- **Lead sponsor:** Chroma Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00737555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00737555, "A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00737555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*